Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 108, Issue 1, Pages 98-108Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s12185-018-2440-4
Keywords
Acute lymphoblastic leukemia; Childhood leukemia; Clinical trial; Novel fusion genes
Categories
Funding
- Children's Cancer Association of Japan
- Grant of the National Center for Child Health and Development [26-20]
Ask authors/readers for more resources
The survival rate of children with acute lymphoblastic leukemia (ALL) has increased to approximately 90% after substantial progress in risk-oriented treatment strategies. Between 2005 and 2013, the Tokyo Children's Cancer Study Group (TCCSG) conducted a risk-oriented, non-randomized study, L04-16. The principal aim of this study was to assemble background characteristics and treatment outcomes, and gather genetic information on leukemic cells under central diagnosis. This report outlines the background characteristics and treatment outcomes of 1033 children with ALL treated according to a TCCSG platform. The 5-year event-free and overall survival (OS) rates for all children were 78.1 +/- 1.3 and 89.6 +/- 1.0%, respectively. The OS rate was significantly higher in children with B-cell precursor (BCP)-ALL (91.9 +/- 1.0%, n = 916) than in those with T-ALL (71.9 +/- 4.3%, n = 117, p < 0.001). In univariate analysis for BCP-ALL, children aged 1-6 years (5y-OS: 94.2 +/- 1.0%), with an initial white blood cell count of < 20,000/mu L (94.0 +/- 1.0%), high hyperdiploidy (95.4 +/- 1.6%), ETV6-RUNX1 (97.4 +/- 1.2%) or TCF3-PBX1 (96.9 +/- 2.1%), and Day8NoBlasts (96.4 +/- 1.1%) had the best outcomes. Genetic investigation revealed two novel fusion genes within this cohort: ETV6-ZNF385A and ZNF362-TCF4. Our study highlighted the clinical aspects of genomic features of ALL in Japanese children. We provide fundamental information for the further molecular investigation of this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available